Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XERS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXeris Biopharma director Jeffrey Sherman retiring at 2026 annual meeting
Filed April 21, 2026 · Period ending April 20, 2026 · ~1 min read
Key Changes
-
low
Dr. Jeffrey Sherman, a board member since 2021 serving on Compensation and Nominating committees, will retire and not seek reelection at the 2026 Annual Meeting.
Item 5.02 verify on EDGAR → -
low
Board size will reduce from eight to seven directors effective at the annual meeting; the company is not replacing Sherman's seat.
Item 5.02 verify on EDGAR → -
low
Company disclosed Sherman's retirement is not due to any disagreement with management or company operations, indicating an amicable departure.
Item 5.02 verify on EDGAR →
Summary
Xeris Biopharma disclosed a routine board transition as Dr. Jeffrey Sherman announced his retirement after five years of service. Sherman, who sits on two key committees overseeing executive compensation and governance matters, will complete his current term through the 2026 Annual Meeting before stepping down. The company emphasized the departure is amicable with no disagreements involved.
For retail investors, this is a low-impact administrative change. Board composition shifts are normal as directors retire, and the reduction from eight to seven members suggests the company views its current board size as appropriate for oversight needs. The explicit 'no disagreement' language is standard SEC disclosure practice to prevent speculation about contentious departures. Watch the proxy statement for the 2026 Annual Meeting to see how committee assignments are redistributed among the remaining seven directors, particularly for the Compensation and Nominating committees where Sherman currently serves.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
In connection with Dr. Sherman’s retirement, the Board has approved a reduction in the size of the Board from eight to seven directors, effective as of the expiration of Dr. Sherman’s term at the 2026 Annual Meeting.
The Board will shrink from eight to seven directors when Dr. Sherman's term ends at the 2026 Annual Meeting. The company is not replacing him with a new director.
Added in current filing · verify on EDGAR →
Dr. Sherman’s decision to retire and not to stand for reelection was not because of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies, or practices.
The company explicitly states that Dr. Sherman's retirement is not due to any disagreement with management or company operations. This is standard disclosure language for director departures to clarify the departure is amicable.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify